Special Section: Vascular Contributions to Alzheimer’s Disease

Pathophysiologic relationship between Alzheimer’s disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis

Cláudia Y. Santos\textsuperscript{a,b}, Peter J. Snyder\textsuperscript{a,h,c}, Wen-Chih Wu\textsuperscript{d}, Mia Zhang\textsuperscript{e}, Ana Echeverria\textsuperscript{f}, Jessica Alber\textsuperscript{a,c,g,*}

\textsuperscript{a}Lifespan Clinical Research Center, Rhode Island Hospital, Providence, RI, USA
\textsuperscript{b}Interdisciplinary Neuroscience Program, University of Rhode Island, Kingston, RI, USA
\textsuperscript{c}Department of Neurology, Warren Alpert Medical School of Brown University, Providence, RI, USA
\textsuperscript{d}Division of Cardiology, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA
\textsuperscript{e}Griffith University School of Medicine, Gold Coast, Queensland, Australia
\textsuperscript{f}University of Puerto Rico School of Medicine, San Juan, Puerto Rico
\textsuperscript{g}Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA

Abstract

As the population ages due to demographic trends and gains in life expectancy, the incidence and prevalence of dementia increases, and the need to understand the etiology and pathogenesis of dementia becomes ever more urgent. Alzheimer’s disease (AD), the most common form of dementia, is a complex disease, the mechanisms of which are poorly understood. The more we learn about AD, the more questions are raised about our current conceptual models of disease. In the absence of a cure or the means by which to slow disease progress, it may be prudent to apply our current knowledge of the intersection between AD, cardiovascular disease, and cerebrovascular disease to foster efforts to delay or slow the onset of AD. This review discusses our current understanding of the epidemiology, genetics, and pathophysiology of AD, the intersection between AD and vascular causes of dementia, and proposes future directions for research and prevention.

© 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords: Alzheimer’s disease; Cardiovascular disease; Cerebrovascular disease; Vascular contributions to cognitive impairment and dementia; VCID; Dementia; Risk factors

1. Introduction

One of the greatest advancements of health in the 20th century was an increase in average life expectancy by 30 years [1]. Today, people aged 85 years and older are the fastest growing segment of the population, and this has led to a new set of problems for modern health care as the elderly are the most susceptible to disease and disability. One in three adults over 85 years old suffer from Alzheimer’s disease (AD) or other forms of dementia [2], the prevalence of which is estimated to increase dramatically over the next 40 years unless preventive measures are developed [3]. AD is currently the sixth leading cause of death in the United States and the cost of the disease is high. Approximately $236 billion will be spent on AD during 2016 calendar year overall, including patient care and caregivers’ lost wages [4].

Despite the global increase of both incidence and prevalence of AD, it is the only leading cause of death that we are currently unable to prevent or cure [5]. The remarkable heterogeneity of risk factors, etiologies, and neuropathologic processes associated with AD makes it especially challenging for development of new treatments to slow disease progression [4,6]. Fortunately, a number of experimental therapies are currently in development. These are aimed
at mechanisms including neurotransmission regulators, tau-based therapies, amyloid-β-based strategies, intracellular signaling cascade modulators, oxidative stress reducers, mitochondrial target therapy, cellular calcium homeostasis modulators, and anti-inflammatory therapies [7–11]. It is possible that the heterogeneity of behavioral presentations, cognitive impairments, and functional statuses observed in AD is due to its potentially varied etiology [12]. Adding to this complexity, older adults with AD typically present with comorbid medical conditions that further complicate accurate disease monitoring [13]. The current dominant AD models are insufficient to account for the complexity of biologic processes, polygenic, and epigenetic factors at work [14]. As a result, key opinion leaders have suggested that the field would benefit from the development of new conceptual models of AD [14]. The purpose of this review is to explore the complex relationship between AD, cardiovascular disease (CVD), and cerebrovascular disease (CBVD). Recent reports that question the strength of the association between these disease entities will be reviewed and recommendations will be made for additional research questions to more precisely characterize causal links between AD, CVD, and CBVD.

2. Shared genetic contributions to AD and cardiovascular disease

The genetic contribution to AD risk is complex. Three familial autosomal-dominant genes associated with early-onset disease have been discovered (PSEN1, PSEN2 and APP) [15–20], and these genes may also be associated with some later onset cases, although together they likely account for less than 10% of all AD cases [21]. The most predominant type of AD is late-onset Alzheimer’s disease (LOAD, referred to herein as AD), which affects adults in their sixth to eighth decade of life. Although many genetic risk factors for AD have been studied, a definitive genotype has not yet been identified [22]. Thus far, few genetic markers have been linked to both AD and CVD. Over the past two decades, numerous studies have shown that individuals who carry at least one copy of the ε4 allele of the apolipoprotein E (APOE) gene are a risk factor for both AD and CVD. Over the past two decades, numerous studies have shown that individuals who carry at least one copy of the ε4 allele have an increased risk for AD compared to those without the ε4 allele [23–26] and ε4 carriers with AD have lower blood levels of apoE [27]. Low plasma levels of apoE protein have been found to increase the risk of AD, independently of APOE genotype [28].

Two polymorphisms (rs1801133, rs1801131) in the methylenetetrahydrofolate reductase (MTHFR) gene correlate with elevated levels of plasma homocysteine and appear to be associated with AD and vascular contributions to cognitive impairment and dementia (VCID) [29,30]. High plasma homocysteine levels have been identified as a risk factor for VCID in a Northern Irish population [29]. Mutations in the MTHFR gene were found to increase the risk of AD by 2.5 fold and VCID by 3.7 fold in an Asian population [30].

Beyond APOE and MTHFR, few other genes have been identified to significantly increase the risk of both AD and CVD. Genetic associations with smaller effects have been found, but a detailed discussion of these is beyond the scope of this review. Recently, new approaches to evaluating genetic pleiotropy in complex diseases have been developed [31]. These methods are now being applied to AD [32], and one recent study demonstrated genetic overlap between AD and CVD by conditioning on CVD phenotypes including C-reactive protein and plasma lipids [33].

3. Shared risk factors for AD and CVD

AD and CVD share important cardiometabolic and lifestyle risk factors that occur in middle-aged to elderly populations. Both AD and CVD are associated with increasing age, and both are among the leading causes of death. The primary causes of CVD are coronary heart disease (CHD), hypertension, stroke, and heart failure. These diseases are frequently interconnected and share an underlying pathology of atherosclerosis. All known risk factors for atherosclerosis have been the focus of studies to identify modifiable risk factors for AD. Researchers from the Framingham Heart Study [34,35] developed a composite measure of general cardiovascular risk, the Framingham Cardiovascular Risk Profile (FCRP), derived by evaluating one’s age, gender, diabetes, smoking, treated and untreated systolic blood pressure (SBP), total cholesterol, and high-density lipoprotein (HDL) cholesterol [36]. In addition to increased risk of CVD, an elevated FCRP score on has been related to markers of abnormal brain aging, such as smaller brain volume and increased white-matter hyperintensities in brain imaging examinations [37]. High FCRP scores are associated with worsening of cognitive abilities, both in cognitively intact subjects and in mild cognitive impairment (MCI) patients [38] and are a reliable predictor of progression from MCI to AD [39]. Other scores developed from Framingham, the Framingham Stroke Risk Profile, and the Framingham Coronary Heart Disease Risk Score, have been similarly associated with cognitive change over time, incident cognitive impairment, and dementia [35,39–43]. These risk models are similar to one developed specifically to assess dementia risk, the Cardiovascular Risk Factors Aging and Dementia (CAIDE) risk score [44–46]. Common elements across scores are blood pressure, cholesterol, and diabetes. In the following, we review elements of these risk scores as they relate to both CVD and AD.

3.1. Hypertension/hypotension

Chronic hypertension, a common risk factor for CVD, causes a thickening of vessel walls, reduced vessel elasticity, and the narrowing of the lumen, especially in small vessels [47,48]. These sequelae result in reduced cerebral blood
flow, a prominent step in the pathophysiology of both AD and CVD. Chronic hypertension also compromises blood–brain barrier (BBB) integrity, leading to both cerebral edema and the introduction of systemic elements into the brain parenchyma [49]. Hypertension recorded 15 years prior has been associated with smaller brain volumes in areas typically affected by AD such as the hippocampus [50]. Our group has observed that an increased resting-state cardiac rate pressure product as a surrogate of myocardial oxygen use has a small to moderate correlation with neocortical amyloidosis in midlife adults with preclinical AD [51].

Epidemiological studies have shown that hypertension is a risk factor for dementia [52–56], but the association is complex [57]. Studies have found that the risk of dementia and AD may vary in strength and direction according to the age of onset [54,55,58,59]. Further complicating these findings, several studies have demonstrated that antihypertensive drugs can reduce the risk of AD [60–64]. Diuretic, angiotensin receptor-1 blocker, or angiotensin-converting enzyme inhibitor use in the Ginkgo Evaluation of Memory Study, was associated with a reduced risk for MCI and AD [61]. Among 2197 participants from the Honolulu–Asia Aging Study who were dementia free at baseline, beta-blocker users experienced a 31% lower risk of developing new cognitive impairments of any cause, compared to those with other antihypertensive or no antihypertensive use [62]. Taken together, these findings suggest that methods to effectively lower BP in midlife, for example, lifestyle changes or medications, should help to retain or improve cognitive function by reducing the risk of AD and/or VCID.

Conversely, there is evidence demonstrating that hypertension in late life is closely associated with a higher risk of AD. The Bronx Aging Study [65] followed a healthy cohort of older adults aged ≥75 years over a median follow-up of 6.7 years. Participants with diastolic blood pressure (DBP) < 70 mm Hg were twice as likely to develop AD as those with DBP >90 mm Hg, and this risk was even higher for subjects with persistently low DBP. Interestingly, there was no such relationship for SBP, and the association between diastolic hypertension and AD was specific; no such association existed for VCID. A pooled analyses of data from the Rotterdam Study (N = 6668) and the Gothenburg H-70 Study (N = 317) found baseline diastolic hypertension was associated with higher risk of AD and/or VCID over an average of 2.1 years of follow-up, and that the risk was more pronounced in antihypertensive medication users [56]. Another population-based study (N = 599, mean age 83.5 years) similarly revealed that lower DBP and SBP were associated with a higher incidence of AD [66]. Extremely low DBP (≤65 mm Hg) produced an adjusted relative risk of 1.7 (95% CI 1.1–2.4) for AD in a prospective study of 1270 individuals aged 75–101 years [67]. Finally, a meta-analysis of 20 population-based studies revealed that a decline in DBP in later life may contribute to diminished cerebral perfusion, and the subsequent ischemic state may lead to increased cerebral Aβ accumulation [68].

3.2. High cholesterol

Cholesterol metabolism plays an important role in the central nervous system (CNS), as the brain is a cholesterol rich organ, comprising 25% of the body’s cholesterol [69]. Studies have indicated that lipoprotein lipase, an enzyme that hydrolyzes triglycerides, may be involved in the biological basis of both AD and CVD (e.g., essential hypertension, CHD) [70–72] through its interaction with brain lipoproteins and modulation of cholesterol homeostasis in neuronal cells [73]. Apolipoprotein E is crucial for the catabolism of triglyceride-rich lipoprotein components and for cholesterol transport [74]. Cholesterol supplied as a lipoprotein complex, such as HDL, is critical for the maturation of synapses and the maintenance of synaptic plasticity [75,76]. Cholesterol levels influence the clearance of Aβ and the formation of neurofibrillary tangles through action at the lipid rafts located in neuronal membranes.

Outside the brain, atherosclerosis is a frequent consequence of high cholesterol and is an important risk factor for ischemic cerebrovascular disease [77]. The contribution of atherosclerosis, a frequent consequence of high cholesterol, is an important risk factor for ischemic cerebrovascular disease [77]. APOE ε4 carrier status is both a risk marker for AD and CVD. In the Rotterdam Study, APOE ε4 carriers with atherosclerosis frequently had comorbid AD and more frequent comorbid VCID [78,79].

Elevated total serum cholesterol levels have been associated with MCI and AD risk in some studies [55,80]. Others have found that the association between cholesterol and AD is complex [81,82]. Similar to hypertension, the risk of dementia associated with high cholesterol may be influenced by the timing and duration of the condition, as well as its treatment. One reason for this complexity is that plasma cholesterol levels do not reflect cholesterol concentrations inside the BBB. The association between high cholesterol and increased risk of AD has resulted in a number of studies testing the hypothesis that statins, which play a role in cholesterol reduction, might prevent the onset or progression of AD. Early epidemiological studies in this area predicted that statins could reduce the incidence of AD by as much as 70% [83–85]. However, whether statins and resultant reduction of cholesterol cause a significant reduction in AD pathology is still unclear. More recent results of large-scale randomized controlled trials suggest no significant clinical benefit of statins in participants at risk for AD [86,87].

3.3. Diabetes mellitus

Diabetes mellitus (DM) is a complex metabolic disorder that is closely associated with changes in cognition as well as other risk factors for accelerated cognitive decline and
dementia, such as hypertension and atherosclerosis [88]. DM occurs when there is a prolonged period of high blood glucose levels or hyperglycemia. There are two types of DM. Type 1 is congenital and caused by insulin deficiency, and type 2 is acquired and caused by insulin resistance.

Although there are points of intersection between the molecular mechanisms underlying diabetes and AD, the exact mechanism of how insulin inefficiency increases the risk of AD remains unknown. The literature is currently separated into two different schools of thought [89]. One follows from Rotterdam study findings, suggesting that the excess of insulin or glucose from type-2 diabetes mellitus (T2DM) leads to AD. This is based on studies demonstrating that AD patients have significantly higher levels of insulin and glucose than healthy controls [90–92]. A second school of thought suggests that insulin deficiency, either due to the relative deficiency that results from insulin resistance in early stages of T2DM, or absolute deficiency that occurs when beta cell dysfunction occurs in full-blown T2DM, causes AD by impairing insulin’s ability to perform its roles in the brain [93–96].

In addition to these two theoretical approaches in the literature, some have suggested the term “type 3 diabetes” was coined to account specifically for the underlying abnormalities associated with concurrent AD-type neurodegeneration and diabetes [97]. These researchers maintain that AD and diabetes share common pathophysiology, and therefore therapeutic regimes aimed at diabetes treatment and amelioration could be effective for treatment of AD [98].

A recent meta-analysis demonstrated a strong link between diabetes and VCI/D [99]. Findings from the Rotterdam study demonstrated a nearly two-fold risk of AD and suggest that DM increases the risk of dementia by 1.9 fold and that DM patients treated with insulin were at even greater risk (4.3 fold) [100]. Multiple population-based studies have shown that patients with DM exhibit an increased risk of developing AD [97,101–103]. The authors of one such study concluded that 39% of AD in a large sample of elderly subjects was attributable to hyperinsulinemia or DM [104].

As with other CVD risk factors, treatment for diabetes has been shown to alter the risk of AD. Metformin has been shown to reduce the risk of AD and is currently being studied in clinical trials with promising preliminary results in MCI patients [105]. A large clinical trial is currently underway to evaluate the efficacy of low-dose pioglitazone as a preventive treatment for MCI due to AD [106]. Other studies have considered the use of intranasal insulin, which has been shown to exert a modest effect on memory performance in AD patients [94,107–109].

4. Lifestyle, behavioral, and environmental risk factors

High-fat diets and sedentary lifestyles have led to a growing incidence of obesity, dyslipidemia, high blood pressure, and metabolic syndromes [110–112]. These conditions are precursors to, or develop along with, atherosclerosis, diabetes, CVD, and an increased risk for AD [113]. Major depression has also been linked to both AD and CVD, and more recently, environmental exposures such as fungal pathogens and pollution have been under investigation for ties to both AD and CVD. In the following, we review the literature that explores obesity, aerobic exercise, smoking, major depression, and exposures such as fungal pathogens and air pollution, each as shared risk factors for both CVD/CBVD and AD.

4.1. Obesity

The mechanism by which obesity influences cognition and AD risk remains under active investigation. One mechanism may be through vascular pathologies, or there may be hormonal, genetic, or inflammatory processes at work [114]. The Framingham Heart Study reported a marked impairment of cognitive function in patients with obesity compared with non-obese counterparts [115]. Epidemiological studies have shown associations between obesity and increased AD risk in females [116,117] although other studies have found increased risk of dementia for both genders [58]. Pooled results from 11 studies [118] demonstrated that the strength and direction of the association vary over the life course. The association between body mass index (BMI) and later onset of AD appears to be stronger when BMI is measured at midlife [119] than when BMI is measured in later life [116,120]. Although they frequently co-occur, DM and obesity are widely accepted as important independent risk factors for AD [121].

4.2. Aerobic exercise and physical fitness

In contrast to metabolic syndromes, aerobic exercise and healthy lifestyles have been shown to reduce the incidence of both CVD and AD in observational studies. Cardiovascular diseases have become very common as communities and individuals attain more wealth and pursue more sedentary lifestyles [121]. Aerobic exercise promotes brain vascularization and may reduce vascular risk factors and improve cognitive function [122–125]. Randomized controlled trials with as little as six months of exercise training lead to increased hippocampal volume and improved performance on spatial memory and executive function tasks [126,127]. Aerobic exercise also upregulates brain-derived neurotrophic factor, which augments plasticity in the hippocampus [128,129].

Epidemiological studies have demonstrated reduced risk of cognitive decline and dementia as a function of activity levels [130–132], and studies have shown increased gray- and white-matter volume in the brains of participants assigned to aerobic training [133] or those with higher levels of self-reported exercise [134]. Recent meta-analysis of clinical trials of exercise interventions in dementia patients demonstrated positive effects [135]. A recent prevention trial of an exercise intervention in sedentary older adults failed to find a significant effect on cognitive function [136]; however, secondary analyses found significant improvement in cognitive function among the subset of participants who were diabetic [137].

A related measure of physical fitness is heart rate variability (HRV) on continuous electrocardiography
recordings. HRV is usually relatively high for those who exercise frequently [138], as well as for young and healthy individuals. Aging and poor physical fitness are associated with an impairment of cardiac vagal function [139], and HRV is lower for those with relatively diminished parasympathetic tone [140], including those with CVD [141]. Vagal tone, the ability of the vagus nerve to rapidly regulate cardiac output, accounts for a substantial portion of HRV. Vagal tone can be quantified via respiratory sinus arrhythmia (RSA), which measures the slight ebb and flow in heart rate that occurs during the respiratory cycle. RSA is higher in older adults who demonstrate better performance on tasks of verbal episodic memory, a cognitive domain that is typically impaired with the onset of AD [142].

In Table 1, we provide a listing of evidence-based interventions for the treatment of CVD, discussed in the sections previously, and how these specific interventions have been explored in the treatment of AD.

### 4.3. Smoking

There is some evidence to suggest that long-term cigarette smoking is an independent risk factor for AD, CVD, and CBVD [159–161]. Smoking increases total plasma homocysteine, an independent risk factor for stroke, cognitive impairment, AD, and other dementias [162–165]. Smoking accelerates atherosclerosis [140] and can cause oxidative stress, which is associated with excitotoxicity, leading to neural death [166]. A dose–response relationship between smoking and dementia risk has been documented [167], and AD risk among smokers is increased in APOE ε4 carriers [100,168]. A meta-analysis of studies performed in the 1990s and early 2000s revealed that relative to nonsmokers, current smokers had increased risks of 1.79 fold (95% CI 1.43–2.23) for AD and 1.78 fold (95% CI 1.28–2.47) for VCID [169]. A more recent systematic review confirmed the previous findings with increased risks of 1.59 fold (95% CI 1.15–2.20) for AD and 1.35 fold (95% CI 0.90–2.02) for VCID [170].

### 4.4. Major depression

A history of major depression is another shared risk factor for AD and CVD. Late-onset depression is often associated with AD, and AD patients with episodes of major depression over their lifetimes show greater hippocampal pathology at autopsy [171]. Evidence exists to suggest that the two disorders may share common etiological substrates [172,173].

| Table 1 | Shared evidence-based treatments for cardiovascular disease (CVD) and Alzheimer’s disease (AD) |
|---|---|
| **Specific medication interventions** | **Clinical effects in treatment of CVD** | **Clinical effects in treatment of AD** |
| **Diuretics** | Thiazide diuretics lead to lowering of blood pressure [143,144]. | Long-term use of diuretics may be associated with decreased incidence of AD [60,61]. |
| Angiotensin receptor-1 blocker (ARB) or angiotensin-converting enzyme (ACE) inhibitor | Reduce risk of cardiovascular events [145,146]. | ARB and ACE inhibitors may slow progression of symptoms in mild–moderate AD [61,63]. |
| **β blockers** | β blockers can prevent cardiovascular events in patients at increased cardiovascular risk [147,148]. | β-blocker use is associated with a lowered risk of developing cognitive impairment in older adults without dementia [62,64]. |
| **Statins** | Reduce risk of cardiovascular events [149,150]. | Mixed literature, with no consistent evidence that statins reduce the incidence of AD or slow cognitive decline [86,87]. |
| **Anti-inflammatory drugs** | Mixed literature on use of nonaspirin anti-inflammatory drugs to reduce cardiovascular risk [151,152]. Low-dose aspirin is commonly used as an anti-platelet agent for secondary CVD prevention. | Mixed literature, suggesting that NSAIDs may confer modest protective effects [10,11]. Low-dose aspirin is commonly used as an anti-platelet agent for stroke prevention. |
| **Insulin treatment** | Effective diabetes treatment confers long-term beneficial effects on risk of CVD [153,154]. | Intrasusal insulin appears to improve cognition and modulates Aβ aggregation in early AD [93,94]. |
| **Specific behavioral interventions** | Long-term protective effects on risk of cardiovascular disorders [155,156]. | Aerobic exercise promotes brain vascularization and may reduce vascular risk factors as well as to improve cognitive function [123,125]. |
| **Aerobic exercise and physical fitness** | Healthy diets may protect against CVD [157,158]. | High-fat diets have shown an increased risk for AD [110,113]. Conversely, carefully designed diets have been shown to confer protective effects [111,112]. |

Abbreviation: NSAIDs, nonsteroidal anti-inflammatory drugs.

NOTE. Given the breadth of this literature, all cited references are exemplars published within the past 10 years, and all are empirical reports.
Chronic, untreated major depressive disorder is associated with the selective loss of noradrenergic cells in the locus coeruleus [174,175] and the loss of dorsal raphe serotonergic nuclei [176], both of which have been demonstrated in AD. Major depression is now widely acknowledged to be a CHD risk factor, based on work demonstrating that psychosocial factors such as chronic dysphoria, anxiety, perceived loss of locus of control, and perceived stress are strongly predictive of incident myocardial infarction [177]. Nearly one of five patients with CVD suffers from major depressive disorder [178]. Depression may be directly linked to cerebral ischemia secondary to reduced cerebral blood flow [178] and is associated with an increased risk of recurrent stroke in patients with VCID [179]. CVD has been proposed as a mediator of the relationship between major depression and AD [180]. Hyperhomocysteinemia has been demonstrated in both AD and major depression [181,182]. Adding to this already complex picture, heightened homocysteine levels are found in CVD [163], indicating a potential shared mechanism in AD, CVD, and major depression. The exact nature of the downstream effects of this mechanism requires further research.

4.5. Fungal pathogens

More recently, fungal macromolecules have been identified as a potential pathophysiological substrate of both AD and CVD. The presence of fungal cells in different sizes and hyphae inside capillaries and other blood vessels in some AD patients suggests that fungal infections can be detected in the neurovascular system and may, in some cases, include, but are not limited to, microvascular degeneration (with looping, twining, and braiding vessels) [194], periventricular venous collagenases, and vascular tortuosity [195]. Unfortunately, many macromolecules with antimicrobial activity have been shown to be cytotoxic toward vascular smooth muscle cells [186], and Aβ is no exception [187]. There is also association of AD with various types of spirochetes, and C pneumonia [188]. However, thus far, to our knowledge, the only documented common fungal or microbial pathogenic link between AD and CVD is Candida albicans. The pathophysiological link between pneumonia and acute cardiovascular events has been explained via the long-lasting infection hypothesis, which implicates microorganisms in atherosclerosis [189].

4.6. Air pollution

Chronic exposure to air pollution, which is associated with reduced HRV, is another environmental factor that is associated with both CVD and AD. Specifically, long-term exposure to high ozone and high particulate matter in the air leads to increased risk for obesity, metabolic syndromes [190], and a host of CVDs [191] including myocardial ischemia and infarction, heart failure, arrhythmias, stroke, and increased cardiovascular mortality [192]. Recently, a dose–response relationship was found between longitudinal exposure to high concentrations of atmospheric particulate matter <10 μm in diameter and significantly increased risk of AD and VCID in industrial regions of Taiwan [193].

5. Co-occurrence of AD and cerebrovascular diseases

CBVD is a generic term from a heterogeneous set of insults to the cerebral vasculature, and such insults often lead to various cognitive impairment(s). CBVD insults include, but are not limited to, microvascular degeneration (with looping, twining, and braiding vessels) [194], periventricular venous collagenases, and vascular tortuosity [195]. These microvascular changes all cause impaired cerebral perfusion [196]. Some studies have shown a correlation between capillary length per brain volume and reduction of glucose utilization [197]. Intracerebral hemorrhages due to Aβ accumulation within vessel walls can contribute to AD pathology [198]. This leads to increased incidence of infarcts in the brain tissue innervated by this system [199]. Collectively, these conditions are considered among the causes for VCID (vascular contributions to cognitive impairment and dementia). VCID refers to a progressive worsening of cognitive functions and memory. VCID is due exclusively to vascular disease within the brain [200]. It is often very difficult to distinguish AD from VCID as they appear very similar on clinical examination. VCID patients often present with episodic memory impairments, word-finding difficulties, disorientation to time, and subtle executive deficits [201]. Thus, a differential diagnosis is aided by careful neuropsychological examination in conjunction with appropriate biomarker studies [202].

In the United States, CBVD is the leading cause of disability in adults and the third leading cause of death [203]. CBVD often plays a direct causal role in cerebrovascular events, as CBVD often results from a lack of blood flow to the brain. Various CBVD pathologies are observed in 60%–90% of AD patients, including white-matter lesions, microinfarcts, hemorrhages, microvascular degeneration, and cerebral amyloid angiopathy (CAA) [74]. CAA is the abnormal deposition of a congophilic material in meningeal and cerebral arterioles. The prevalence of CAA is high in AD and CAA often progresses in severity causing vessel rupture [204]. Atherosclerosis, a common cause of CBVD, can lead to cerebral infarction or stroke, and disabling cognitive impairments in late life [205]. Many large population-based epidemiologic studies have provided strong support for the relationship between AD and cerebrovascular changes. One such study examining two large cohorts of AD patients found a strong relationship between AD and cerebral atherosclerosis, such that the presence of atherosclerosis was associated with worse cognitive performance in AD [206]. The Framingham Heart Study found that a lower cardiac index was
associated with increased risk of AD [207]. These findings suggest that age-related changes in systemic hemodynamics may contribute to the pathogenesis or exacerbation of amyloid deposition, subsequent neuronal injury, and vascular pathology [207]. Similar findings have been reported for other large epidemiologic studies, including the Pittsburgh Cardiovascular Health Study [208] and the Prospective Population Study of Women in Gothenburg, Sweden [209]. Likewise, the Atherosclerosis Risk in Communities study found a high prevalence of magnetic resonance imaging (MRI)-detected cerebral abnormalities, related to cognitive functioning, that might reflect preclinical AD [210].

As described previously and across a large body of published literature, VCID can manifest solely as a result of CBVD events, such as hemorrhagic or ischemic strokes, or by the accumulation of multiple ischemic events. However, it remains unclear whether AD occurs in the absence of any vascular pathology, or whether CVD and CBVD changes are mechanistically related to the fundamental pathology of AD. Two separate imaging studies have recently cast doubt on the interdependence of AD and vascular pathologies [211,212]. The studies suggest that AD-related amyloid burden and CBVD independently affect cognitive impairment, as there was no correlation between the images comparing specific neuroanatomic coordinates of both amyloidosis (positron emission tomography [PET] PIB ligand binding) and white-matter hyperintensities (WMHs) with structural MRI. In a study of 251 cognitively impaired subjects, Ye et al. found that PIB retention ratios were associated with both hippocampal atrophy and memory impairments and, conversely, the WMH imaging was more strongly associated with frontal cortex thinning and executive dysfunction. The authors concluded that the effect on cognition for individuals with both pathologies was additive and not synergistic; thus, the impact of AD and CVD pathologies on cognition is mediated through independent mechanisms [212]. Vemuri et al. (2015) evaluated MRI and PET images from 393 cognitively normal participants, aged 70–90 years from the Mayo Clinic Study of Aging and showed that for subjects with both vascular and amyloid pathologies, the effect of both pathologies on cognition was additive and not synergistic [211]. Both Ye and Vemuri et al. have put forward similar arguments, but they are based on a single MRI imaging marker of CBVD. However, as we outline in the following, cardiovascular and cerebrovascular pathologies are highly complex clusters of biological processes that share many points of mechanistic links to AD. These two recent imaging studies stand as outliers within a large body of literature suggesting that although VCID may frequently occur in the absence of AD, the converse is not necessarily true.

6. AD, CVD, and CBVD: shared pathophysiology and neuropathological substrates

AD, CVD, and CBVD primarily affect the same at-risk population who share many common risk factors. All three diseases may independently and/or interdependently lead to debilitating, unremitting, and progressive changes in cognition. The direct causal relationship between vascular and cerebrovascular insults, and dementia or apoplexia, was described over three centuries ago by Thomas Willis [213]. Medical practitioners generally considered dementia to result from vascular insults. As early as 1833, Lobstein used the term “dementia arteriosclerotica” attributing the nature of the disease to vascular origins [214]. A causal link between other nonvascular brain disease states and dementia was not well described until the latter half of the 19th century. In 1871, Charles Darwin received a letter from the director of England’s largest lunatic asylum, Dr. James Crichton-Browne, who observed that senile decay was the result of central nervous system disease that was linked to emotional liability [173]. Thirty-six years later, the initial case report of Alois Alzheimer’s; described the finding of senile plaques and neurofibrillary tangles found on postmortem histopathology examination of a patient who had “ordinary dementia” and neuropsychiatric symptoms [215].

Prof. Alzheimer presaged the complexity and multicausality of dementia by reporting atherosclerosis in the cerebral blood vessels of his 55-year-old patient, for which he coined the term Alzheimer’s sclerosis [216]. The term AD was reserved for the diagnosis of dementia with onset between ages 40 and 90 years, if the other causal explanations (e.g., vascular causes) of dementia were absent [217]. The National Institute of Aging (NIA) and the Alzheimer’s Association (AA) revised the diagnostic and research criteria for AD in 2011, and this reformulation of the diagnostic nosology were detailed in three publications that year [218–220]. According to the new NIA-AA criteria, a diagnosis of “preclinical AD” is based on the presence of relevant positive biomarkers (e.g., PET amyloid imaging) in conjunction with known risk factors for the disease (e.g., APOE ε4 allele). The identification of individuals in this stage of prodromal AD is made essentially for research purposes only [218]. MCI due to AD includes patients with mild cognitive symptoms (impaired performance on measures of episodic memory function) with positive evidence of the disease from appropriate biomarker studies [219]. Ultimately, a diagnosis of AD is now based on criteria that account for recent developments in disease-specific biomarkers, which allow for confirmation of AD without the need to rely on postmortem histopathology [220–222].

In the following, we briefly review the major overlapping pathophysiology between CVD, CBVD, and AD, all of which is briefly summarized in Table 2.

6.1. Reduced cerebral blood flow

Normal brain function is dependent on receiving 20% of the cardiac output of oxygenated blood, and both higher and lower blood pressure may reduce this cerebral blood flow [227]. Hence, impaired cardiac function may subsequently lead to both reduced intracranial blood flow (e.g., as
measured within the Circle of Willis) and ischemia, and this is readily observed in AD patients [228]. Reduced cerebrovascular reactivity was observed in a study of 18 young adult (mean age 24 years) carriers of at least one APOE ε4 allele [229]. Suri et al. surmise that this lifelong relative decrease in cerebral blood flow will lead to areas of hypoperfusion and microvascular damage; thereby, contributing to aggregation of blood products, endothelial dysfunction, and impaired Aβ clearance [229]. It is of note that the sample size in this study was small, and further investigation is required to elucidate the nature of the interaction between cerebral blood flow, APOE status, and AD. A meta-analysis was conducted to investigate whether the changes in cerebral blood flow velocity and pulsatility index by Doppler ultrasonography in AD and VCID follow similar patterns. Both disease states were found to be associated with pronounced disturbances in cerebrovascular hemodynamics, with VCID patients showing significantly lower cerebral blood flow [230].

Another factor that may contribute to reduced regional cerebral blood flow is the observed decrease of endothelial nitric oxide (NO) synthesis in AD [231]. The enzyme endothelial nitric oxide synthase (eNOS) is responsible for NO generation, which is important for cardiovascular homeostasis and acts as a vasodilator involved in the control of vasomotor function and local blood flow [232]. Endothelial production of NO is important for the prevention of CBVD, as it mediates protection from stroke by preserving cerebral blood flow and preventing inflammation, thrombosis, and apoptosis [233]. Besides the CBVD contributions, it can also increase expression of APP and BACE1, consequently increasing Aβ levels [234]. The evolving opinion is that cerebrovascular dysfunction is not only present in CBVD but also a prominent component of neurodegenerative pathologies such as AD [235].

6.2. Aβ deposition

The amyloid cascade hypothesis postulates that neurodegeneration in AD is due to an abnormal accumulation of Aβ plaques in various areas of the brain [236], and the neurodegenerative processes in AD are the consequence of the imbalance between Aβ peptide production and clearance [237]. Recently, Yau et al. provided clear support for targeting Aβ clearance in early AD based on their longitudinal study of 16 patients with an autosomal-dominant mutation for early-onset AD. In their study, they demonstrated that amyloidosis is one of the earliest events in the neuropathological cascade leading to AD, with the majority of Aβ aggregation occurring before the progressive structural neurodegeneration and cognitive decline [238].

The abnormal aggregation of Aβ protein in the brain neurophil may lead to either diffuse plaques and/or concentrated neuritic plaques, with the latter form of deposits often present in the vicinity of the cerebral microvasculature [239]. The Aβ protein, with its crystalline molecular structure, infiltrates the vessel walls and compromises the BBB [239]. Deposition of Aβ protein within the walls of cerebral blood vessels also leads to CAA, increasing the risk of cerebral hemorrhage [74], which is the most common clinical presentation of CAA [240]. In an APP/PS1 transgenic mice study with induced hyperhomocysteinemia, Sudduth et al. showed that congophilic amylloid deposition was decreased in the parenchyma and significantly increased in the vasculature in CAA. This suggests that CBVD can significantly impact Aβ distribution in the brain by vascular deposition and that such deposition can induce microhemorrhages and activate neuroinflammation [241]. In an in vivo study of Sprague–Dawley rats, infusion of solubilized Aβ peptides enhanced constriction of cerebral and peripheral vessels, contributing to cerebral hypoperfusion and leading to decreased blood flow and increased vascular resistance [242].
The risk of both repeated hemorrhagic strokes, as well as ischemic events due to vessel wall stenosis and oligemia, increases with continued Aβ accumulation for both CAA and AD patients. This pathologic cascade leads to medial temporal lobe atrophy, cognitive decline, and progressive brain atrophy [74]. Finally, vascular Aβ deposits observed in AD have been shown in vitro to induce degeneration of human and murine cerebral microvascular smooth muscle and endothelial cells, resulting in vasoconstriction, intraluminal thickening, inhibiting angiogenesis, impairing vascular tone, and decreasing total cerebral blood flow [243].

6.3. Morphological changes in the vasculature

Arterial stiffness can be caused by structural or cellular change within vessel walls, and amyloid deposition in the vessels leads directly to this pathophysiological process [244]. The fragmentation of elastin alters the hemodynamics of vessel walls, resulting in increased systolic pressure by increasing the speed of the arterial wave that arrives prematurely during systole rather than during diastole [245]. Atherosclerosis also accelerates arterial stiffness [246], a frequent finding in patients with CVD. Arterial stiffness is a clear risk factor for cognitive impairment in later life, as it can cause structural changes in the brain, such as white matter or cortical infarcts and cortical brain atrophy [247,248]. A recent systematic review of this association concludes that arterial stiffness is related to cerebral small vessel disease and decreased cognitive function [249].

The deposition of Aβ in arterial vessel walls, and subsequent impediment of perivascular drainage of Aβ due to AD pathology, can lead to intracerebral hemorrhage and an increase of Aβ peptides [74]. These morphological and architectural changes of the cerebral vasculature, studied in APP23 tg mice, start early in life. Along with the increase in observable amyloid plaques, there is also increased atrophy and altered blood flow, suggesting that disrupted microvasculature integrity can contribute to the progression of AD [250]. However, subtle changes in cerebral microcirculation are difficult to measure with high precision for the exploration of longitudinal changes within subjects associated with increased disease burden. These subtle morphological changes may be more easily observed in the microvasculature of the retina. Patients with AD have sparser retinal microvascular networks and other structural alterations that may mirror pathophysiological events found in the cerebral microvasculature [251]. Patients with AD show changes in retinal microvasculature, such as more tortuous retinal vessels and a narrowing of retinal venules [252]. These retinal vascular changes have been posited to precede the majority of neurodegeneration that characterizes AD progression [48].

6.4. Alterations in BBB permeability

The brain vasculature has cellular elements forming a developmental, structural, and functional relationship with the brain tissue termed the neurovascular unit [244]. The neurovascular unit has a fundamental role in the broad spectrum of pathologies underlying cognitive impairment. Neural activity requires continuous and regulated blood flow to activate neurons, astrocytes, and vascular cells through a wide variety of molecular signals (ions, arachidonic acid, metabolites, NO, adenosine, neurotransmitters, and neuro-peptides) [253]. Specific neuroimaging techniques to visualize deleterious changes to the BBB are still under exploration. Several studies have shown that plasma proteins like prothrombin, which are typically excluded from the CNS, can be found within the microvessel walls and surrounding neuropil in AD patients, showing that the leakage of the BBB may be frequent in AD [254]. The vascular abnormalities found in the AD brain, such as alteration in smooth muscle cells and pericytes, endothelial cell thinning, loss of endothelial mitochondria, and thickening of the vascular basement membrane, all contribute to alterations in BBB permeability [255]. The end result is a continuous cycle of reduced cerebral perfusion leading to acceleration of the neurodegenerative process, which further reduces perfusion.

The changes in BBB permeability lead to an ionic imbalance and accumulation of toxic metabolic products. As a consequence, synaptic, neuronal, and oligodendroglial dysfunction occurs [256] because an intact BBB is crucial for limiting the entry of toxic products and cells into the brain. Glucose transport across the BBB is also impaired, and PET studies show reduced regional metabolic rate in the AD brain [257]. Alterations on the (Na+/K+)-pump function of the BBB can result in fluid balance impairment, leading to deregulation of regional cerebral blood flow [258].

Aβ accumulation can contribute to the leakage of the BBB [259]. These peptides, spread across a defective BBB, contribute to higher oxidative and nitrosative damage, as well as increased protease activity [74]. Aβ deposition leads to microglial activation, reactive astrogliosis and a multiprotein inflammatory response [260]. Studies of WT and APOE deficient mice show that BBB permeability increases with age and a defect in the BBB is exacerbated in APOE deficient mice [261,262]. Additionally, arterial stiffness results in an uncoupling of the neurovascular unit, and this disruption of the cerebral microenvironment is likely to contribute to brain dysfunction [263]. The resulting accumulation of Aβ in the neuropil and vessel walls leads to the activation of neuroinflammatory response, which plays an important role in BBB disruption [264]. Anatomically, neuroinflammation may lead to transient increases in thickness of various cortical tissues, as well as at least one neuronal cell layer of the retina in preclinical stage disease. Snyder et al. (2016) have provided initial evidence to suggest an increase in the thickness of the retinal inner plexiform layer, in preclinical AD, and they postulate this volume increase may be partly due to a localized neuroinflammatory process and/or deposition of amyloid-containing inclusion.
6.5. Cholinergic neurodegeneration

Postmortem studies have shown reduced activity of choline acetyltransferase, decreased numbers of nicotinic acetylcholine receptors, and reduced basal forebrain cholinergic neurons (particularly in the nucleus basalis of Meynert), contribute to the oldest model of neurobiologic dysfunction in AD—the “cholinergic hypothesis” [266,267].

This reduction in cholinergic innervation and activity may result, in part, from a reduction in noradrenaline release due to locus coeruleus (LC) neuron loss [268]. There is a strong reciprocal connection between the LC and the prefrontal cortex, and this area is involved in the mediation of executive functioning, memory, and vigilance [269]. The LC is responsible for exerting an excitatory influence on wakefulness-promoting nuclei, such as the cholinergic nuclei of the septal area, medial preoptic area and substantia innominata [270]. Pathological changes in the LC occur early in AD [271], and this reduction in LC activity likely leads to the common finding of reduced levels of arousal and alertness in AD patients. The number of LC neurons projecting to areas such as the hippocampus and the frontal cortex declines slowly with normal aging, and this may result in some modest age-related changes in spatial learning and memory [272].

This structural and functional loss in the LC affects both efferent and afferent pathways. The LC exerts both direct (via a descending excitatory noradrenergic pathway) and indirect effects (via modulation of the activity of other premotor sympathetic nuclei) on preganglionic sympathetic neurons in the intermediolateral cell column [273]. The LC sends efferent inputs to the nucleus tractus solitarius, which is critical for the modulation of the vasomotor response to changes in blood pressure through vagal nerve stimulation and autonomic inputs to the heart. The vagal nerve provides cholinergic input to increase parasympathetic activity, which decreases heart rate and lowers blood pressure when needed [274].

The earliest stages of AD are marked, in part, by altered function of the basal forebrain cholinergic system, with eventual degenerative changes including neuronal loss [275,276]. We have recently reported that a downregulation of central cholinergic neurotransmission appears to be one of the earliest neuropathological changes in preclinical AD [277], and we have also found that individuals with evidence of both decreased central cholinergic tone and amyloid aggregation within the anterior cingulate region show evidence of increased resting cardiac workload at rest [51]. The aggregation of Aβ plaques in the neocortex, within this specific region of interest that is part of the central cholinergic system, appears to be directly associated with increasing cognitive impairment as well as the higher myocardial oxygen consumption at resting state [51]. In fact, there is a growing body of literature to suggest a direct link between Aβ aggregation, basal forebrain cholinergic damage, and diminished cholinergic innervation of cortical blood vessels, leading to the microvascular pathology that has been documented in the majority of AD cases [278–281]. We are currently exploring whether indices of phasic vagal cardiac control, such as RSA and HRV, are also related to cortical amyloidosis in preclinical AD because both RSA and HRV are directly modulated by muscarinic cholinergic and nicotinic autonomic neurotransmission.

7. Discussion

This review is intended to tie together several lines of research on the shared mechanistic relationships between AD, CVD, and CBVD. The literature that binds these diseases is both large and confusing. Why is AD so tightly connected to disruption of the cerebrovasculature and to cardiologic disease? Why do these broad disease entities share so many risk factors and mechanistic relationships? One compelling answer to these larger questions may come from the field of medical anthropology and attempts to study the global distribution of APOE gene alleles across the human species. The ε4 allele is the ancestral form of APOE [223,224] and is associated with both higher absorption of cholesterol at the intestinal level and higher plasma cholesterol levels in carriers. The phenotypic expression of this allele would likely confer a survival benefit to humans that evolved with limited food supplies and in harsh weather conditions. Expression of the ε4 allele under contemporary/modern diet, exercise, and environmental conditions, together with the relatively recent and dramatic increase in human longevity, may have now led to the identification of the ε4 allele as pleiotropic, showing susceptibilities for both CVD and AD [224]. Although this anthropological viewpoint is not universally accepted, nor the focus of the current review, it affords us an overarching heuristic model to explain the strong relationship between CVD, CBVD, and AD.

Another question that arises from the frequent co-occurrence of AD, CVD, and CBVD is whether or not they are the end result of shared etiologic mechanisms. If one supposes a direct, bidirectional causal link between these disease clusters, then all cases of CVD and/or CBVD would also demonstrate AD pathology, and we know this is not the case. Rather, we have reviewed a large literature indicating that vascular/cerebrovascular pathology is present for most individuals with AD but not all of them. In support of this notion, an autopsy study with the largest cohort to date (N = 5715) showed increased prevalence of CBVD and vascular pathology in AD compared to healthy controls and patients with dementias of non-AD etiologies [225]. Additionally, a recent autopsy study combining two well-known longitudinal cohorts (the Religious Orders Study
and the Rush Memory and Aging Project, $N = 1143$) revealed an increased risk of incident AD dementia with the presence of CBV pathology. There was a stepwise increase in the odds ratio for AD development with the severity of CBV pathology, suggesting that this pathology is a risk factor for AD development [206].

So what, then, is the causal nature of the relationships between these diseases? To answer this question, it is important to determine whether the cognitive effects of AD and CVD/CBVD are additive or synergistic. This is a topic that continues to elicit considerable scientific exploration. It is possible that AD and CVD/CBVD contribute independently to dementia, such that the severity of the dementia is a cumulative result of two separate pathologies [210]. Alternatively, these disease processes could be synergistic, such that the pathology of one accelerates the progress of the other. The majority of the literature reviewed herein supports the model of a synergistic interaction between vascular/cerebrovascular and neurodegenerative processes early in disease pathogenesis. This theory is further supported by a reciprocal relationship between Aβ accumulation and cerebrovascular insult such that Aβ deposition provokes vascular/cerebrovascular changes [74] and vice versa [282,283]. Clinical studies demonstrate that even mild cerebrovascular pathology results in reduced cognitive performance in very early AD [77,284]. It is possible that both additive and synergistic processes are affecting cognitive decline at different stages of these disease processes. This theory is congruous with variability in observational findings based on timing, severity, and duration of CVD risk factors. In fact, it has been suggested that later disease stages could demonstrate a more additive relationship [285].

There is evidence that vascular/cerebrovascular pathology can accelerate the progression of preclinical AD and speed disease evolution [286,287]. The relationships between AD and CVD/CBVD are complex, and further investigation is required to discern the exact nature of these relationships at different stages of disease progression. We suggest that, because AD is so frequently accompanied by comorbid vascular and/or cerebrovascular symptoms, it is both clinically and scientifically relevant to consider these pathologies concurrently, regardless of whether their respective underlying pathologic mechanisms are independent and additive, or functionally related and synergistic.

We support the widely studied hypothesis that effectively controlling vascular risk factors serves to delay onset of AD. In fact, a recent statement by the World Dementia Council suggested that “Regular physical activity and management of cardiovascular risk factors (e.g., diabetes, obesity, inactivity, hypertension) are associated with a reduced risk of cognitive decline and may reduce the risk of dementia” [288,289]. A recent cross-sectional study concluded that the use of certain medications to treat vascular disease, especially angiotensin receptor blockers and diuretics, may decrease Aβ accumulation [290]. In a recent review, Deckers et al. (2015) [291] found that the most common modifiable risk factors for AD development included hypertension, diabetes, midlife obesity, physical inactivity, hyperlipidemia, and smoking. Simple, inexpensive interventions involving diet and exercise in midlife could be very useful tools to prevent CVD, CBVD, and AD. These interventions are currently under evaluation by several large prospective clinical trials, including the CAIDE [292] and the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER [293]). Nonetheless, preliminary results indicate that the complex multifactorial nature of AD requires interventions that simultaneously target multiple risk factors and disease mechanisms during the preclinical stage of the disease [292,293]. The CAIDE screening tool has been developed based on vascular and metabolic factors shown to increase dementia risk to identify individuals who are at risk for dementia and who require preventive intervention [44], and this has recently been developed into a freely available smartphone application [292].

The validation of sensitive and reliable measures of dementia risk that account for CVD susceptibility (e.g., CAIDE), paired with lifestyle intervention techniques to control or reduce these same risk markers, will ultimately lead to a better understanding of the relationship between these two disease clusters. The exploration of the dynamic pathogenic relationships between AD and CVD/CBVD has the potential to lead to a reduction and/or delay in AD incidence. In accordance with earlier work revealing that interactions between mechanistic, genetic, and lifestyle factors influence vascular disease, we expect that these multifactorial interventions targeting common mechanistic and lifestyle factors in AD and CVD/CBVD will confirm that the adoption of a heart-healthy lifestyle has the potential to contribute to a future decline in all three disease processes.

7.1. Future directions

Despite the rapid advancement of medical technology, we are still developing a suite of reliable and sensitive diagnostic markers to identify individuals at risk for AD before onset of clinical symptoms. This is an area of research that needs to be urgently addressed to enable the study of early interventions to maintain quality of life in premorbid AD and to reduce the individual and societal burden of the disease. There are currently several secondary prevention trials aimed at pharmacologically slowing or reducing the Aβ accumulation that occurs in preclinical AD, but as of this writing, these secondary prevention trials are still in progress and we do not yet have successful therapies to prevent or slow/reduce disease progression. It is typically the case that such large prospective studies seek to exclude participants with significant cardiovascular or cerebrovascular comorbidities. Given the evidence supporting a substantial overlap of epidemiology, genetics, risk factors, and mechanistic factors in vascular and AD pathology, we argue that future secondary prevention
trials should focus on a more heterogeneous and phenotypically representative population.

Aside from clinical trials and recruitment science, there continues to be an outpouring of literature aimed at untangling the mechanistic relationships between CVD, CBVD, and AD. Recently, the National Institutes of Health launched the Molecular Mechanisms of the Vascular Etiology of Alzheimer’s Disease Consortium, the primary aim of which is to construct a comprehensive model of Alzheimer’s disease that more accurately reflects its complex underpinnings, and the multiple pathways of disease development. The main objectives of this initiative are to elucidate the complex mechanisms by which cardiovascular risk factors influence the development and progression of AD and to identify new targets for treatment and prevention. Thus far, the consortium supports five project areas addressing a wide range of topics, including the following: the contribution of Alzheimer’s risk genes (APOE ε4) to AD and CVD; the contribution of DM to AD, CVD, and CBVD; the contribution of hypertension to AD development and progression; identifying metabolic signatures underlying risk factors for both AD and CVD; and investigating the mechanism of Aβ accumulation and clearance at the molecular, single-blood vessel, and whole-brain level and the relationship of Aβ accumulation at all three levels in AD and CBVD. Moving forward, studies such as these that investigate the interaction of vascular biology with genetic, cardiometabolic, and lifestyle risk factors and AD pathology will be crucial to the development of therapeutic agents.

There are many questions about the relationships between AD, CBVD, and CVD that remain unanswered. One important public health question is how these diseases intersect in the oldest-old. The World Health Organization has reported a worldwide dementia incidence of 47.5 million in 2015, and a projected incidence of 75.6 million in 2050. The largest risk factor for AD, CVD, and CBVD is increasing age. In the United States, the population of adults aged ≥90 years is expected to grow over six-fold by 2050 [285]. As the average lifespan increases, the social and economic consequences of AD, CVD, and CBVD are expected to expand accordingly. Because of difficulties in finding, recruiting, and diagnosing the oldest-old, very little literature exists examining the relationships between AD, CBVD, and CVD in this population. Future population-based studies should aim to include this cohort to further understand the nature of disease interactions over time and to identify prevention targets to reduce cardiovascular risk (i.e., blood pressure, glycemic index, and cholesterol levels) in these specific populations. More accurate models are required for assessing prognosis and life expectancy in older adults with AD, CVD, and/or CBVD in the context of multiple chronic conditions.

Acknowledgments

None of the authors have any conflicts of interest to disclose. This article was first-authored by C.Y.S. in partial fulfillment of her Ph.D. dissertation project, for which P.J.S. serves as her major professor and dissertation advisor. The authors thank Drs. Zaven Khatchaturian, Ara Khachaturian, and Kathleen Hayden for very helpful comments as this article was prepared. P.J.S. dedicates this work to the loving memory of his stepfather, Edward L. Etkind, M.D. (1936–2015).

RESEARCH IN CONTEXT

1. Systematic review: The authors conducted online searches for all the relevant literature describing the relationship between Alzheimer’s disease (AD), cardiovascular disease (CVD), and cerebrovascular disease (CBVD). A thorough review of common epidemiology, risk factors, and possible mechanistic pathways that might link these three entities is provided.

2. Interpretation: There is a substantial overlap in epidemiologic, genetic, and clinical literature of shared risk factors for AD and cardiovascular and cerebrovascular comorbidities. There is also very substantial overlap in shared mechanistic relationships between AD and both CVD and CBVD. We suggest that vascular/cerebrovascular pathology is present for most individuals with AD, although the converse is not necessarily true.

3. Future directions: Further investigation is required to understand the mechanistic pathways for shared pathology between these two constellations of diseases. Our group and others are tracking vascular changes in preclinical AD patients. Epidemiological studies of CVD progression promise new insights on the effects of subclinical CVD on the brain. Currently ongoing cardiovascular prevention trials impacting dementia risk will provide substantial insight into the possibility of delaying the onset of AD.

References

[1] Oeppen J, Vaupel JW. Broken limits to life expectancy. Science 2002; 296:1029–31.
[2] Christensen K, Dobhlammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet 2009;374:1196–208.
[3] Hebert L, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology 2013;80:1778–83.
[4] Alzheimer’s Association. 2015 Alzheimer’s disease facts and figures. Alzheimer’s Dement 2015;11:332.
[5] van Norden AGW, van Dijk EJ, de Laat KF, Scheltens P, OldeRikkert MGM, de Leeuw FE. Dementia: Alzheimer pathology
and vascular factors: From mutually exclusive to interaction. Biochim Biophys Acta 2012;1822:340–9.

[6] Au R, Piers RJ, Lancashire L. Back to the future: Alzheimer’s disease heterogeneity revisited. Alzheimer’s Dement 2015;1:1:368–70.

[7] Nygaard HB. Current and emerging therapies for Alzheimer’s Disease. Clin Ther 2013;35:1480–9.

[8] Latta CH, Brothers HM, Wilcock DM. Neuroinflammation in Alzheimer’s disease: a source of heterogeneity and Target for personalized therapy. Neurosci 2015;302:103–11.

[9] Barage SH. Sonawane KD Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer’s disease. Neuropeptides 2015;52:1–18.

[10] Arvanitakis Z, Grodstein F, Bienias JL, Schneider JA, Wilson RS, Kelly JF, et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neuror 2008;70:2219–25.

[11] Leoutsakos JMS, Muthen BO, Breitner JCS, Lyketsos CG. Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer’s Disease Anti-Inflammatory Pre- vention Trial. Geriatr Psychiatry 2012;27:364–74.

[12] Collins JL, Vinters HV, Cole GM, Khachaturian ZS. Effects of apolipoprotein E4 and parental family history of Alzheimer’s disease. Neurology Clin 2014;4:730–42.

[13] Wang C, Yu JT, Wang HF, Jiang T, Tan CC, Meng XF, et al. Meta-analysis of peripheral blood apolipoprotein E levels in Alzheimer’s disease. PLoS One 2014;9:e89041.

[14] Rasmussen KL, Tybjærg-Hansen A, Nordestgaard BG, Frikk- Schmidt R. Plasma levels of apolipoprotein E and risk of dementia in the general population. Ann Neurol 2015;77:301–11.

[15] McLlroy SP, Dyan KB, Lawson JT, Patterson CC, Passmore AP. Moderate elevated plasma homocysteine, Methyleneentetrahydro- late Reductase Genotype, and Risk for Stroke, Vascular Dementia, and Alzheimer Disease in Northern Ireland. Stroke 2002; 33:2351–6.

[16] Mansoori N, Tripathi M, Luthra K, Alam R, Lakshmy R, Sharma S, et al. MTHFR (677 and 1298) and IL-6-174 G/C genes in pathogen- esis of Alzheimer’s and vascular dementia and their epistatic interaction. Neurobiol Aging 2012;33:1003.e1–8.

[17] Andreassen OA, Djurovic S, Thompson WK, Schork AJ, Kendler KS, O’Donovan MC, et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet 2013; 92:197–209.

[18] Yokoyama JS, Wang Y, Schork AJ, Thompson WK, Karch CM, Cruchaga C, et al. Alzheimer’s Disease Neuroimaging Initiative: Association between genetic traits for immune-mediated diseases and Alzheimer disease. JAMA Neurol 2016;73:691–7.

[19] Desikan RS, Schork AJ, Wang Y, Thompson WK, Dehghan A, Ridker PM, et al. Inflammation Working G, International Genomics of Alzheimer’s Disease P, DemGene I. Polynomic overlap between C- reactive Protein, Plasma Lipids, and Alzheimer disease. Circulation 2015;131:2061–9.

[20] Dabwer TE, Meadows GF, Moore FE Jr. Epidemiological approaches to heart disease: the framingham study. Am J Public Health Nations Health 1951;41:279–81.

[21] Harrison SL, Ding J, Tang EY, Siervo M, Robinson L, Jagger C, et al. Cardiovascular disease risk models and longitudinal changes in cognition: a systematic review. PLoS One 2014;9:e114431.

[22] Kanne WB, McGee D, Gordon T. A general cardiovascular risk profile: The Framingham study. Am J Cardiol 1976;38:46–51.

[23] Gudlaugsson E, Rausen H, Brix M, Tsai WH, Switalski R, Mosconi L, et al. Framingham cardiovascular risk profile correlates with impaired hippocampal and cortical vasoactivity to hypercapnia. J Cereb Blood Flow Metab 2011;31:671–9.

[24] Jefferson AL, Hohman TJ, Liu D, Haj-Hassan S, Gifford KA, Benson EM, et al. Adverse vascular risk is related to cognitive decline in older adults. J Alzheimers Dis 2015;44:1361–73.

[25] Viticci G, Falletti L, Buratti L, Bobia C, Luzzi S, Bartolini M, et al. Framingham risk score can predict cognitive decline progression in Alzheimer’s disease. Neurobiol Aging 2015;36:2940–5.

[26] Laughlin GA, McEvoy LK, von Mühlen D, Daniels LB, Kritz- Silverstein D, Bergstrom J, et al. Sex differences in the association of Framingham Cardiac Risk Score with cognitive decline in community-dwelling elders without clinical heart disease. Psychoso- som Med 2011;73:683–9.

[27] Dregan A, Stewart R, Gulliford MC. Cardiovascular risk factors and cognitive decline in adults aged 50 and over: a population-based cohort study. Age Ageing 2013;42:338–45.

[28] Kaffashian S, Dugravot A, Elbaz A, Shipley MJ, Sabia S, et al. Candidate gene for the chromosome 1 familial Alzheimer’s disease type 3 gene. Nature 1995;376:775–8.

[29] Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer’s disease. Science 1991;349:704–6.

[30] Lack of apolipoprotein E dramatically reduces amyloid beta peptide deposition. Nat Genet 1997;17:263–4.

[31] Cervera A, Adluru N, Destiche DJ, Lu SY, Doran ST, Birdsill AC, Melah KE, et al. White matter microstructure in late middle-age: Effects of apolipoprotein E4 and parental family history of Alzheimer’s disease. Neurology Clin 2014;4:730–42.
De Jong GI, De Vos RA, Steur EN, Luiten PG. Cerebrovascular Exalto LG, Quesenberry CP, Barnes D, Kivipelto M, Biessels GJ, Skoog I. Vascular aspects in Alzheimer’s disease. J Neural Transm Santos CY, Lim YY, Wu WC, Polynice S, Schindler R, Maruff P, et al. Skoog I, Gustafson D. Update on hypertension and Alzheimer’s dis-

Whitmer RA. Midlife risk score for the prediction of dementia four decades later. Alzheimers Dement 2014;10:562–70.

Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, et al. Effects of Cardiovascular Medications on Rate of Functional Decline in Alzheimer Disease. Am J Geriatr Psychiatry 2008;16:883–92.

Verghese J, Lipton RB, Katz MJ, Hall CB, Derby CA, Kuslansky G, et al. Leisure Activities and the Risk of Dementia in the Elderly. N Engl J Med 2003;348:2508–16.

Nilsson SE, Read S, Berg S, Johansson B, Melander A, Lindblad U. Low systolic blood pressure is associated with impaired cognitive function in the oldest old: longitudinal observations in a population-based sample 80 years and older. Aging Clin Exp Res 2007;19:41–7.

Qiu C, Van Strauss E, Fastbom J, Winblad B, Fratiglioni L. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol 2003;60:223–8.

Kennelly SP, Lawlor BA, Kenny RA. Blood pressure and dementia – a comprehensive review. Ther Adv Neurol Disord 2009;2:241–60.

Björkhem I, Meaney S, Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004;24:806–15.

Baum L, Wiebusch H, Pang CP. Roles for lipoprotein lipase in Alz-
heimer’s disease: an association study. Microsc Res Tech 2000;50:291–6.

Blain JF, Aumont N, Théroux L, Dea D, Poireir J. A polymorphism in lipoprotein lipase affects the severity of Alzheimer’s diseasepathophysiology. Eur J Neurosci 2006;24:1245–51.

Xie C, Wang ZC, Liu XF, Yang MS. The common biological basis for common complex diseases: evidence from lipoprotein lipase gene. Eur J Hum Genet 2010;18:3–7.

Blain JF, Poireir J. Cholesterol homeostasis and the pathophysiology of Alzheimer’s disease. Expert Rev Neurother 2004;4:823–9.

Kalaria RN, Akiniyemi R, Ihara M. Does vascular pathology contribute to Alzheimer changes? J Neurol Sci 2012;322:141–7.

Koudinov AR, Koudinova NV. Essential role for cholesterol in synap-
aptic plasticity and neuronal degeneration. FASEB J 2001;15:1858–60.

Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001;294:1354–7.

Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and clinical expression of Alz-
heimer’s disease: the Nun Study. JAMA 1997;277:813–7.

Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harsskamp F, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam study. Lancet 1997;349:151–4.

Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002;155:487–95.

Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease. Neuroepidemiology 1998;17:14–20.

Mielke MM, Zandi PP, Shao H, Waern M, Ostling S, Guo X, et al. The 32-year relationship between cholesterol and dementia from midlife to late life. Neurology 2010;75:1888–95.

Mielke MM, Zandi PP, Sjogren M, Gustafson D, Ostling S, Steen B, et al. Total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005;64:1698–95.

Wölözín B, Kellman W, Ruusseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-
hydroxy-3-metylgulatryl coenzyme A reductase inhibitors. Arch Neu-
rol 2000;57:1439–43.
Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010;74:956–64.

McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev 2009; 2:CD003160.

Bissels GJ, Stackenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006;5:64–74.

Schilling MA. Unraveling Alzheimer’s: Making Sense of the Relationship between Diabetes and Alzheimer’s Disease. J Alzheimer’s Dis 2016;51:961–77.

Carantoni M, Zuliani G, Munari MR, D’Elia K, Palmieri E, Fellin R. Alzheimer disease and vascular dementia: Relationships with fasting glucose and insulin levels. Dement Geriatr Cogn DIS 2000; 11:176–8.

Razay G, Wilcock GK. Hyperinsulinemia and Alzheimer’s disease. Age Ageing 1994;23:396–9.

Fujisawa Y, Sasaki K, Araki K. Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type. Biol Psychiatry 1991;30:1219–28.

Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al. Intrasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69:29–38.

Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, et al. Intrasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008;70:440–8.

Freiherr J, Hallschmid M, Frey WH II, Bruenner YF, Chapman CD, Hoelscher C, et al. Intrasal Insulin as a treatment for Alzheimer’s disease: A review of basic research and clinical evidence. CNS Drugs 2013;27:505–14.

Tabot K, Wang H-Y, Kazi H, Han L-Y, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012;122:1316–38.

de la Monte SM. Type 3 diabetes is sporadic Alzheimer’s disease: mini-review. Eur Neuropsychopharmacol 2014;24:1954–60.

Ahmed S, Mahmood Z, Zahid S. Linking insulin with Alzheimer’s disease: emergence as type III diabetes. Neurolog Sci 2015;36:1763–9.

Chatterjee S, Peters SA, Woodward M, Mejia Arango S, Batty GD, Beckett N, et al. Type 2 Diabetes as a Risk Factor for Dementia in Women Compared With Men: A Pooled Analysis of 2.3 Million People Comprising More Than 100,000 Cases of Dementia. Diabetes Care 2016;39:300–7.

Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999;53:1937–42.

Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L. Cardiovascular and cerebrovascular diseases. Oxford textbook Public Health Pract Public Health 2009; 64:392–8.

Whiteman A, Young DE, He X, Chen TC, Wagenaar RC, Stern C, Colcombe SJ, Erickson KI, Raz N, Webb AG, Cohen NJ, McAuley E, McTiernan A, et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol 2010;67:71–9.

C.Y. Santos et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 7 (2017) 69-87
recognition memory in healthy young adults. Behav Brain Res 2014; 259:302–12.

[130] Yaffe K, Barnes D, Nevitt M, Lui LY, Covinsky K. A prospective study of physical activity and cognitive decline in elderly women: women who walk. Arch Intern Med 2001;161:1703–8.

[131] Podevoli LI, Guallar E, Kuller LH, Fried LP, Lopez OL, Carlson M, et al. Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. Am J Epidemiol 2005;161:639–51.

[132] Larson EB, Wang L, Bowen JD, McCormick WC, Teri L, Crane P, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 2006;144:73–81.

[133] Colcombe SJ, Erickson KI, Scalf PE, Kim JS, McAuley E, et al. Aerobic exercise training increases brain volume in aging humans. J Gerontol A Biol Sci Med Sci 2006;61:1166–70.

[134] Papenberg G, Papenberg N, Holmberg S, Milgrom E, Thies F, et al. The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. Ageing Res Rev 2016;25:13–23.

[135] Groot C, Hao-ghiemstra AM, Rijmers MK, van Berckel BN, Scheltens P, Scherder EJ, et al. The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. Ageing Res Rev 2016;25:13–23.

[136] Sink KM, Espeland MA, Castro CM, Church T, Cohen R, Dodson JA, et al. Effect of a 24-month physical activity intervention vs health education on cognitive outcomes in sedentary older adults: the LIFE randomized trial. JAMA 2015;314:781–90.

[137] Espeland MA, Lipska K, Miller ME, Rushing J, Cohen RA, Verghese J, et al. Investigators flLS. Effects of Physical Activity Intervention vs Health Education on Cognitive Function in Sedentary Adults With and Without Diabetes. J Gerontol A Biol Sci Med Sci 2016; glw179.

[138] Demeersman RE. Heart-rate-variability and aerobic fitness. Am J Heart 1993;125:726–31.

[139] Tulppo MP, Mäkiikallio TH, Seppänen T, Laukkanen RT, Huikuri HV. Vagal modulation of heart rate during exercise: effects of age and physical fitness. Am J Physiol Heart Circ Physiol 1998;274:424–9.

[140] Kemp AH, Quintana DS. The relationship between mental and physical health: insights from the study of heart rate variability. Int J Psychophysiol 2013;89:288–96.

[141] Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol 2010;141:122–31.

[142] Dywan J, Mathewson KJ, Chomka BL, Rosenfeld B, Segalowitz SJ. Autonomic and electrophysiological correlates of emotional intensity in older and younger adults. Psychophysiology 2008;45:389–97.

[143] Basile BN, Bloch MJ. Determining the relative antihypertensive potency and relative cardiovascular risk reduction associated with different thiazide and thiazide-type diuretics. JCH 2013;15:359–61.

[144] Malaco E, Mancia G, Rappelli A, Menotti A, Zuccaro MS, Coppini A, Shell Investigators. Treatment of isolated systolic hypertension: the SHELL study results. Blood Press 2013;12:160–7.

[145] Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amiodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417–28.

[146] Yusuf S, Teo K, Anderson C, Pogue J, Dybal L, Copland F, et al. Effects of the angiotensin–receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174–83.

[147] Toffler GH, Spinaze M, Shaw E, Buckley T. Therapy for triggered acute risk prevention in subjects at increased cardiovascular risk. Am J Cardiol 2013;111:1755–8.

[148] Shaw E, Toffler GH, Buckley T, Bajorek B, Ward M. Therapy for triggered acute risk prevention: a study of feasibility. Heart Lung Circ 2009;18:347–52.

[149] Kendrick J, Shipak MG, Targher G, Cook T, Lindenfeld J, Chonchol M. Effect of Lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am J Kid Dis 2010;55:42–9.

[150] Tikkanen MJ, Fayyad R, Faergeman O, Olsson AG, Wun CC, Laskey R, et al., IDEAL Investigators. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013;168:3846–52.

[151] Valentina P, West W, Cannuccio CC, Watson DJ, Walker AM. Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmaepidemiol Drug Safe 2006;15:641–52.

[152] Rouimie CL, Choma NN, Kaltenbach L, Mitchell EF, Arboagast PG, Griffin MR. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events–stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacopoeidim Drug Safe 2009;18:1053–63.

[153] Cederholm J, Zethelius B, Nilsson PM, Eeg-Olofsson K, Elisson B, Guddbjornsdottir S. Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diabetes Res Clin Pract 2009;86:74–81.

[154] Varma S, Piatt GA. The effect of controlling the ABC’s of diabetes on cardiovascular disease in a community-based endocrinology practice. JDM 2013;3:4.

[155] Spertetta GF, Silva AA, Vendramini RC, Zanesco A, Delbin MA, Menani JV, et al. Resistance training prevents the cardiovascular changes caused by high-fat diet. Life Sci 2016;146:154–62.

[156] Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of cardiovascular events. potential mediating mechanisms. Circulation 2007;116;19.

[157] Dehghan M, Mente A, Teo KK, Gao P, Sleight P, Dagenais G, et al. Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention. Circulation 2012;126:2705–12.

[158] Rumawas ME, Meigs JB, Dwyer JT, McKeown NM, Jacques PF. Mediterranean-style dietary pattern, reduced risk of metabolic syndrome traits, and incidence in the Framingham Offspring cohort. Am J Clin Nutr 2009;90:1608–14.

[159] Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005;65:545–51.

[160] Varma S, Poultter R, Warner J, Beckett N, Burch L, Bulpit C. Smoking, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatr 2008;8:36.

[161] Cataldo JK, Prochaska JJ, Grant SA. Cigarette smoking is a risk factor for Alzheimer’s Disease: an analysis controlling for tobacco industry affiliation. J Alzheimers Dis 2010;19:465–80.

[162] Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003;138:891–7.

[163] Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 2002;359:545–51.

[164] Sachdev PS, Parsons RA, Lux O, Salnikov C, Wen W, Naidoo D, et al. Relationship of homocysteine, folic acid and vitamin B12 with depression in a middle-aged community sample. Psychol Med 2005;35:529–38.

[165] Seidah S, Wolf PA, Beiser AS, Selhub J, Whelton PK. Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol 2010;67:642–9.

[166] Ambrose JA, Banya RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004;43:1731–7.

[167] Giunta B, Deng J, Jin J, Sadic E, Run M, Zhou H, et al. Evaluation of how cigarette smoke is a direct risk factor for Alzheimer’s disease. Technol Innov 2012;14:39–48.
[212] Ye BS, Seo SW, Kim GH, Noh Y, Cho H, Yoon CW, et al. Amyloid burden, cerebrovascular disease, brain atrophy, and cognition in cognitively impaired patients. Alzheimer Dement 2015;11:494–503.

[213] Willis T. Instructions and prescripts for curing the apoplexy. In: Pordage S, ed. The London Practice of Physic or the Whole Practical Part of Physic; 1679. Dring T, Harper C, Leigh J, Martyn S.

[214] Lobstein J. Traite d’anatomie pathologique. Levraut Paris 1833:2.

[215] Alzheimer A. Über einen eigenartige Erkrankung der Hirrinde. Allg Z Psychiatr Psych Gericht Med 1907;64:146–8.

[216] Alzheimer A. Über eigenartige Krankheitsfälle des spateren Alters. Zeitschrift für die gesamte Neurologie und Psychiatrie 1911;11:356-85.

[217] Groth T, Bartus R, Ferris SH, Whitehouse P, Cohen GD, Gershon S. Age associated memory impairment: proposed diagnostic criteria and measures of clinical change-report of a National Institute of Mental Health Work Group. Dev Neuropsychol 1986;2:261–76.

[218] Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer Dement 2011;7:280–92.

[219] Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer Dement 2011;7:270–9.

[220] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer Dement 2011;7:263–9.

[221] Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer Dement 2011;7:257–62.

[222] Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimer Dement 2012;8:1–13.

[223] Hanlon CS, Rubinsztein DC. Arginine residues at codons 112 and 129 in APP/PS1 transgenic mice. Alzheimers Res Ther 2014;6:32.

[224] Corbo RM, Scacchi R, Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thirfy’ allele? Ann Hum Genet 1999;63:301–10.

[225] Toledo JB, Arnold SE, Raible K, BrettSchneider J, Xie SX, Grossman M, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative cases in the National Alzheimer’s Coordinating Centre. Brain 2013;136:2697–706.

[226] Kaffashian S, Dugravot A, Nabi H, Batty GD, Brunner E, Kivimäki M, et al. Predictive utility of the Framingham general cardiovascular disease risk profile for cognitive function: evidence from the Whitehall II study. Eur Heart J 2011;32:2326–32.

[227] Stukas S, Robert J, Wellington CL. High-density lipoproteins and cerebrovascular integrity in Alzheimer’s disease. Cell Metab 2014;19:574–91.

[228] Berman SE, Rivera-Rivera LA, Clark LR, Racine AN, Keevil JG, Bratze L, et al. Intracranial arterial 4D-flow is associated with metrics of brain health and Alzheimer’s disease. Alzheimer Dement 2015;11:420–8.

[229] Suri S, Mackay CE, Kelly ME, Germsuka M, Tunbridge EM, Frisoni GB, et al. Reduced cerebrovascular reactivity in young adults carrying the APOE ε4 allele. Alzheimer Dement 2015;11:648–57.

[230] Sàbyan B, Jansen S, Oleskis AM, van Osch MIP, van Buchem MA, van Vliet P, et al. Cerebrovascular hemodynamics in Alzheimer’s disease and vascular dementia: A meta-analysis of transcranial Doppler studies. Ageing Res Rev 2012;11:271–7.

[231] Austin SA, Santhanan AV, Hinton DJ, Choi DS, Katusic ZS. Endothelial nitric oxide deficiency promotes Alzheimer’s disease pathology. J Neurochem 2013;127:691–700.

[232] Katusic ZS, Austin SA. Endothelial nitric oxide: protector of a healthy mind. Eur Heart J 2014;35:888–94.

[233] Atochin DN, Huang PL. Endothelial nitric oxide synthase transgenic models of endothelial dysfunction. Pfugers Arch 2010;460:965–74.

[234] Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer’s disease. Nat Rev Neurosci 2004;5:347–60.

[235] Gorelick PB, Sutterti A, Black SE, DeCarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:2672–713.

[236] Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992;256:184–5.

[237] Patterson BW, Elbert DL, Mawuenyega KG, Kasten T, Ovod V, Ma S, et al. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann Neurol 2015;78:439–53.

[238] Yau WWY, Tudorascu DL, McDade EM, Ikonomovic S, James JA, Minhas D, et al. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer’s disease: a prospective cohort study. Lancet Neurol 2015;14:804–13.

[239] Blennow K, Wallin A, Fredman PK, Gottfries CG, Svennerholm L. Blood-brain barrier disturbance in patients with Alzheimer’s disease is related to vascular factors. Acta Neurol Scand 1990;81:323–6.

[240] Keable A, Fenna K, Yuen HM, Johnston DA, Smyth NR, Smith C, et al. Deposition of amyloid β in the walls of human leptomeningeal arteries in relation to perivascular drainage pathways in cerebral amyloid angiopathy. Biochim Biophys Acta 2016;1862:1037–46.

[241] Sudduth TL, Weekman EM, Brothers HM, Braun K, Wilcock DM. β-amyloid deposition is shifted to the vasculature and memory impairment is exacerbated when hyperhomocysteinemia is induced in APP/PS1 transgenic mice. Alzheimers Res Ther 2014;6:32.

[242] Suo Z, Humphrey J, Kundrata A, Sethi F, Placzek A, Crawford F, et al. Soluble Alzheimers β-amyloid constricts the cerebral vascular bed. Neurosci Lett 1998;257:77–80.

[243] Miao J, Xu F, Davis J, Holler IO, Verbeek MM, Nostrand WEV. Cerebral microvascular amyloidβ protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloidβ precursor protein. Am J Pathol 2005;167:505–15.

[244] Hughes T, Kuller L, Barinas-Mitchell E, McDade E, Mackey R, Mathis C, et al. Arterial Stiffness is associated with amyloid deposition in the brain independent of blood pressure. Alzheimer Dement 2013;9:19–20.

[245] O’Rourke MF, Safar ME, Dzau V. The cardiovascular continuum extended aging effects on the aorta and microvasculature. Vas Med 2010;15:461–8.

[246] Hughes TM, Craft S, Lopez OL. Review of the potential role of arterial stiffness in the pathogenesis of Alzheimer’s disease. Neurodegener Dis Manag 2015;5:121–35.

[247] Henry-Feugeas MC, Roy C, Shouman-Claeys W. Leukoaraisosis and pulse-wave encephalopathy: observations wit phase-contrast MRI in mild cognitive impairment. J Neuroradiol 2009;36:212–8.

[248] Nichols W, O’Rourke M, Vlahopoulos C. McDonald’s Blood flow in Arteries. 6th ed. London: Arnold; 2011.

[249] Singer J, Trollor JN, Baune BT, Sachdev PS, Smith E. Arterial stiffness, the brain and cognition: A systematic review. Ageing Res Rev 2014;15:16–27.

[250] Meyer EP, Ulmman-Schuler A, Staufenbier M, Krucker T. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer’s disease. Proc Natl Acad Sci U S A 2008;105:3587–92.
Grudzien A, McGowan AJ, Cardwell CR, Cheung CY, Craig D, Passmore P, et al. Retinal microvascular network attenuation in Alzheimer’s disease. Alzheimer Dement 2015;1:229–35.

Cheung CY, Ong VT, Ikram MK, Ong SY, Li X, Hilal S, et al. Microvascular network alterations in the retina of patients with Alzheimer’s disease. Alzheimer Dement 2013;10:135–42.

Drake CT, Iadecola C. The role of neuronal signaling in controlling cerebral blood flow. Brain Lang 2007;102:141–52.

Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulett CM, et al. Microvascular injury and blood-brain barrier leakage in Alzheimer’s disease. Neurobiol Aging 2007;28:977–86.

Kalaria RN. Cerebral vessels in ageing and Alzheimer’s disease. Pharmacol Ther 1996;72:193–214.

Zlokovic BV. Neurovascular mechanisms of Alzheimer’s neurodegeneration. Trends Neurosci 2005;28:4.

Heiss WD, Kessler J, Szlesz B, Grond M, Fink G, Herholz K. Position emission tomography in the differential diagnosis of organic dementias. J Neural Transf Suppl 1991;33:13–9.

Cataldi M. The changing landscape of voltage-gated calcium channels in neurovascular disorders and in neurodegenerative diseases. Curr Neuropharmacol 2013;11:276–97.

Hartz AM, Bauer B, Soldner EL, Wolf A, Boy S, Backhaus R, et al. Amyloid-beta contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebrovascular amyloid angiopathy. Stroke 2012;43:514–23.

McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995;21:195–218.

Hafezi-Moghadam A, Thomas KL, Wagner DP. ApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage. Am J Physiol 2007;292:1256–62.

Metters N, Andre P, Hafezi-Moghadam A, Economopoulos M, Thomas KL, Wagner DP. ApoE deficiency compromises the blood brain barrier especially after injury. Mol Med 2001;7:810–5.

Girouard H, Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer’s disease. J Appl Physiol 2006;100:328–35.

Chaitanya GV, Cromer W, Wells S, Jennings M, Mathis M, Minagar JM, et al. Metabolic modulation of cytokine-induced brain endothelial adhesion molecule expression. Microcirculation 2012;19:155–65.

Snyder PJ, Johnson LN, Lim YY, Santos CY, Alber J, Maruff P, Fernandez B. Nonvascular retinal imaging markers of preclinical Alzheimer’s disease. Alzheimer Dement 2016;4:149–78.

Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 1976;2:1403.

Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Trends Neurosci 2005;28:4.

Benarroch EE. Central neurotransmitters and neuromodulators in cardiovascular regulation. In: Bannister R, Mathias CJ, eds. Automatic Failure. 3rd Edition. Oxford: Oxford University Press; 1992. p. 36–53.

Herring N, Danson EJF, Paterson DJ. Cholinergic control of the heart rate by nitric oxide in site specific. News Physiol Sci 2002;12:202–6.

Beach TG, Honer WG, Hughes LH. Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: the preclinical stage of Alzheimer’s disease? Acta Neuropathol 1997;93:146–53.

Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Beh Brain Res 2011;221:555–63.

Lim YY, Maruff P, Schindler R, Ott BR, Salloway S, Yoo DC, et al. Disruption of cholinergic neurotransmission exacerbarates Aβ-related cognitive impairment in preclinical Alzheimer’s disease. Neurobiol Aging 2015;36:2709–15.

Kouznetsova E, Schliebs R. Role of cholinergic system in B-amyloid related changes in perivascular innervation of cerebral microvessels in transgenic Tg2576 Alzheimer-like mice. J Neurochem 2007;101:63.

Bürger S, Noack M, Kirazov LP, Kirazov EP, Naydenov CL, Kouznetsova E, et al. Vascular endothelial growth factor (VEGF) affects processing of the amyloid precursor protein and B-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain. Int J Dev Neurosci 2009;27:517–23.

De la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002;33:1152–62.

Kalaria RN. The role of cerebral ischemia in Alzheimer’s disease. Neurobiol Aging 2000;21:321–30.

Jendroska K, Poewe W, Daniel SE, Pfleiss J, Iwersen-Schmidt P, Paulsen J, et al. Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. Acta Neuropathol 1995;90:461–6.

Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 2010;120:287–96.

Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer’s disease. Lancet 1999;354:919–20.

Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 2004;62:1148–55.

Helzner EP, Luchsinger JA, Scarmeas N, Costantino S, Bruckman AM, Glymour MM, et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 2009;66:343–8.

Silverstein M, Pasqualetti P, Baruffaldi M, Bartolini M, Handouk Y, Mattei M, et al. Cerebrovascular reactivity and cognitive decline in patients with Alzheimer disease. Stroke 2006;37:1010–5.

Steven C. World Dementia Council issues risk reduction statement. Global action against dementia. Alzheimer’s Association Statement; 2015.

Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimer Dement 2015;11:718–26.

Globzik L, Rusiniek H, Kamer A, Pirraglia E, Tsui W, Mosconi L, et al. Effects of vascular risk factors, statins and antihypertensive drugs on PiB deposition in cognitively normal subjects. Alzheimer Dement 2015;11:718–26.